108 articles - From Friday Sep 19 2025 to Friday Sep 26 2025
Guidelines and related publications, position statements, white papers, technical reviews, consensus statements, etc…
| Gastroenterology |
|---|
AGA Clinical Practice Guideline on Management of Gastroparesis. The diagnosis of gastroparesis requires the use of 4-hour gastric emptying tests. Metoclopramide or erythromycin is appropriate for initial pharmacologic treatment. Other treatment recommendations require shared patient-physician decision making. There are still considerable unmet needs in the treatment of gastroparesis. |
meta-analyses and systematic reviews
| Aliment Pharmacol Ther |
|---|
Meta-Analysis: Mortality Trends and Risk Factors in Severe Alcohol-Associated Hepatitis. Short-term mortality in sAH remains high and has not improved in recent decades. These findings highlight the urgent need for effective therapies, improved patient selection for early liver transplantation, and better prognostic tools to guide clinical decision-making. |
Systematic Review: Ultrasound Goes Echo-Decarbonising Inflammatory Bowel Disease Care Through Intestinal Ultrasound. GI endoscopy, CT and MRI are indispensable in IBD care but carry considerable environmental costs. The broader adoption of IUS offers a clinically effective, low-carbon alternative that can contribute to more sustainable IBD management, aligning with planetary health goals. |
| Clin Gastroenterol Hepatol |
Performance of Fecal Immunochemical Test in Individuals with Personal history of Polyps and Family History of Colorectal Cancer: A Systematic Review. Current evidence is limited to adequately assess diagnostic performance of FIT in individuals with family history of CRC, or as follow up after polypectomy. |
RCT, clinical trials, retrospective studies, etc…
| Aliment Pharmacol Ther |
|---|
Cost-Utility Analysis of Biomarker-Based vs. USG + AFP Strategies for HCC Surveillance in Chronic Hepatitis B. ASAP every 6 months is the most cost-effective HCC surveillance strategy for patients with CHB and may be particularly suitable for resource-limited settings. Biomarker-based surveillance should be prioritised to improve outcomes and optimise resource use. |
Exploration of Multiple Non-Invasive Tests for Assessing Response to Treatment in a Semaglutide Phase 2b Trial in Patients With MASH. NITs may be used for assessing a treatment response in patients with MASH. Further studies should confirm the treatment effect of NITs and evaluate the association of NIT changes to outcomes. |
Non-Response to Obeticholic Acid Is Associated With Heightened Risks of Developing Clinical Events in Primary Biliary Cholangitis. Biochemical response stratifies risk of clinical events in PBC patients under OCA treatment. Whilst response rates increase over time, discontinuation rates underscore the need for newer treatment paradigms. |
Research Communication: The Cumulated Spontaneous Portosystemic Shunts (SPSS) Area Decreases After TIPS and Impacts on Prognosis. Relative SPSS area decrease was an independent protective factor for mortality (asHR: 0.19; 95% CI: 0.04-0.88; p = 0.034). In conclusion, SPSS decrease after TIPS and relative SPSS area change is independently linked to survival, while total shunt area remains unaltered. |
| Clin Gastroenterol Hepatol |
Behavioral Interventions Improve Mailed Colorectal Cancer Screening Among Overdue Patients in a Randomized Trial. Behaviorally-informed text messaging and mailed reminders significantly increased screening completion, but the health system branded box did not increase response rates. |
Differential Effects of Cardiometabolic Risk Factors on All-Cause Mortality in US Adults with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). In age-adjusted analysis, number of CMRFs was associated with greater risk for mortality (aHR 1.15 per additional CMRF, 95%CI 1.10-1.20, p<0.001) CONCLUSIONS: The differential risk for mortality between individual CMRFs supports distinct clinical profiles in MASLD. This study found that high blood pressure and glucose intolerance exerted the greatest risk for all-cause mortality in those with MASLD, suggesting a role for prioritization of CMRF optimization. |
Prevalence of fibrosis and applicability of lab-based non-invasive tests from primary to tertiary care. Prevalence of fibrosis in contemporary SLD patients was ∼7% in primary/secondary care, being especially pronounced in individuals with diabetes or obesity. LiverPRO and LiverRisk score optimize referral pathways. |
| Endosc Int Open |
Minimum standards for training in colorectal endoscopic mucosal resection among advanced endoscopy trainees. The relatively low number of C-EMRs performed by many AETs may be insufficient to achieve competence. The estimated thresholds for an average AET to achieve competence in C-EMR provide a framework for AETPs in determining the minimal standards for case volume exposure during training. |
Narrow band imaging complements eosinophilic esophagitis reference score in predicting inflammatory infiltration in patients with dysphagia. Positive NBI signs and furrows were the best predictors of eosinophile infiltration, whereas lymphocytic infiltration was predicted by edema. Given that NBI is already widely available, we encourage use of both white light and NBI in patients with suspected esophageal inflammation. |
| Gastrointest Endosc |
Endosonography guided Coloenterostomy for Palliative Management of Peritoneal Carcinomatosis. EUS-guided CE for palliative management of SBI caused by peritoneal carcinomatosis is feasible and safe. The intervention boasts a high clinical success rate with immediate symptom relief and significant improvement of symptom-compensated and overall survival. |
| Gut |
Alleviated T cell exhaustion and SLC1A3-mediated stroma-remodelling dictate chemoimmunotherapy efficacy in oesophageal squamous cell carcinoma. This study elucidates the synergistic mechanisms and identifies key resistance pathways underlying chemo-immunotherapy combinations in patients with ESCC, providing a scientific basis for refining future combination therapeutic regimens. |
Gastrin-dependent expansion of Cck2r<sup>+</sup> corpus progenitors accelerates ulcer healing and inhibits gastric dysplasia. We report a novel role for G-cell-derived gastrin in ulcer healing. Hypogastrinaemia is a risk factor for poor ulcer healing, corpus atrophy and potentially cancer, while physiological gastrin responses are protective. PPI-induced hypergastrinaemia plays a key role in ulcer healing, and gastrin signalling may prevent gastric preneoplasia. |
Glycaemic control is a modifiable risk factor for pancreatic cancer development in patients with diabetes: a population-based cohort study. Optimal glycaemic control was associated with lower PC risk in T2D. Further multicentre cohort studies are warranted to confirm its oncopreventive strategy. |
| Hepatology |
'Point-of-Care Ultrasound (POCUS) guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis'. POCUS facilitates volume management and AKI reversal in cirrhosis. CCM predicts poor outcomes in HRS-AKI, need for RRT, and mortality. |
Bile acid signaling in MASLD: from pathogenesis to therapeutic applications. Therapeutic strategies targeting these BA receptors along the gut-liver axis, either directly through agonists or indirectly via modulation of BA transport, are currently within the focus of clinical research. This review summarizes mechanistic aspects of BA signaling in MASLD, key evidence of experimental and clinical studies on BA receptor agonists and provides an outlook for future opportunities and challenges on the road to the implementation of novel therapies targeting BA receptors and BA signaling in MASLD. |
Evolving Precision: Updates in Targeted Therapy for Cholangiocarcinoma. We will provide an overview of available single-gene analyses that should be considered in case of lack of access to NGS, defining testing priorities, differences in yields, and therapeutic implications. Lastly, we will discuss future perspectives in the field of precision medicine for BTC, focusing on new strategies to overcome treatment resistance, on the optimal collocation of targeted drugs in the treatment algorithm, and on newly identified actionable alterations for which compounds are currently under investigation. |
| J Hepatol |
Nivolumab plus ipilimumab for potentially resectable hepatocellular carcinoma: long-term efficacy and biomarker exploration. Neoadjuvant nivolumab plus ipilimumab followed by surgery is feasible and might improve long-term survival in patients with potentially resectable HCC. Immunotherapy-induced TLS formation is associated with enhanced antitumor immunity. Clinical trial number NCT03510871. |
Strategies to address non-proportional hazards between survival curves - Lessons from phase III trials in hepatocellular carcinoma. NPH caused discrepancies in IMbrave050's interim and subsequent efficacy analyses. Robust IA requires a minimum follow-up duration or number of events before prematurely stopping an RCT with NPH. Impact and implications Non-proportional hazards (NPH) impact phase III RCTs in hepatocellular carcinoma (HCC), particularly in immunotherapy trials, potentially causing discrepancies between the interim and final analyses. In fact, halting trials at the interim analysis can be premature when NPH is present. Thus, we propose a framework to ensure study maturity based on follow-up duration and event accruals to optimize interim analyses in the presence of NPH. Whenever NPH is identified, distinct statistical tools should be used to assess reliable differences between arms (MaxCombo) and to assess the effect size [restricted mean survival time (RMST) and piecewise hazard ratios (pHR)] for regulatory decisions and clinical guidance. Implementing these strategies can improve trial design, and better support decision-making for HCC management. |
Plenty of the editorials are available as full text through the publisher website using the provided link
| Gastrointest Endosc |
|---|
| Gut |
AI-empowered human microbiome research. Additionally, we explore the transformative impact of AI on translational applications across both academic research and real-world clinical settings, including disease diagnostics, therapeutic development and precision microbiome engineering. By critically evaluating the current capabilities and limitations of AI in this context, this review aims to chart a path forward for the integration of AI into microbiome research, ultimately accelerating innovations in personalised medicine and deepening our understanding of host-microbiome relationships. |
Epigenetic therapies in hepatocellular carcinoma: emerging clinical tools and applications. Importantly, we discuss how targeting epigenetic mechanisms may not only suppress tumour growth but also enhance the effectiveness of current therapies by reversing resistance pathways. By translating complex molecular insights into tangible therapeutic strategies, epigenetics is poised to reshape the future of HCC management, offering renewed hope for more durable and personalised treatment responses in a disease where progress is urgently needed. |
misc publications eg case reports, tools of the trade, images of the month, etc…
| Am J Gastroenterol |
|---|
| Clin Gastroenterol Hepatol |
| Endosc Int Open |
| Endoscopy |
| Gastroenterology |
| Gut |
| Hepatology |
| J Hepatol |
Letters to the editors and authors’ replies
| Aliment Pharmacol Ther |
|---|
| Clin Gastroenterol Hepatol |
| Gastrointest Endosc |
| Gut |
| J Hepatol |